Home › Mantle Cell Lymphoma
Mantle Cell Lymphoma clinical trials recruiting in the U.S.
71 studies for Mantle Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Baldwin Park, CA16 studies
- Houston, TX15 studies
- Seattle, WA13 studies
- Durham, NC13 studies
- Milwaukee, WI12 studies
- Columbus, OH12 studies
- New York City, NY12 studies
- Boston, MA11 studies
- Nashville, TN10 studies
- Chicago, IL10 studies
- Portland, OR9 studies
- Rochester, MN9 studies
- St. Louis, MO8 studies
- Denver, CO8 studies
- Atlanta, GA8 studies
- Los Angeles, CA7 studies
- Mountain View, CA7 studies
- Cleveland, OH7 studies
- Salt Lake City, UT6 studies
- Dallas, TX6 studies
- Jacksonville, FL6 studies
- Ann Arbor, MI6 studies
- Miami, FL6 studies
- San Diego, CA5 studies
- Buffalo, NY5 studies
- Kansas City, MO5 studies
- Tampa, FL5 studies
- Washington, DC5 studies
- New Haven, CT5 studies
- Baltimore, MD5 studies
- Edison, NJ5 studies
- Charlotte, NC5 studies
- Philadelphia, PA5 studies
- San Francisco, CA4 studies
- Providence, RI4 studies
- Charlottesville, VA4 studies
- Birmingham, AL4 studies
- Pittsburgh, PA4 studies
- Richmond, VA4 studies
- Omaha, NE4 studies
By state
- Alabama4 studies
- Arizona6 studies
- California31 studies
- Colorado10 studies
- Connecticut6 studies
- Delaware3 studies
- Florida16 studies
- Georgia9 studies
- Illinois10 studies
- Indiana4 studies
- Iowa5 studies
- Kansas7 studies
- Kentucky4 studies
- Louisiana3 studies
- Maryland9 studies
- Massachusetts13 studies
- Michigan8 studies
- Minnesota14 studies
- Missouri8 studies
- Nebraska4 studies
- New Jersey8 studies
- New York16 studies
- North Carolina17 studies
- Ohio17 studies
- Oregon10 studies
- Pennsylvania9 studies
- Rhode Island4 studies
- Tennessee11 studies
- Texas19 studies
- Utah6 studies
- Virginia7 studies
- Washington15 studies
- Wisconsin13 studies
Recently updated studies
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06252675A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06697184A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06742996Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06784167Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06553872A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06029309Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07225439Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07003295A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Sep 2, 2026 · NCT05976763A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07673367AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Aug 10, 2026 · NCT05887167A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06542250Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Aug 7, 2026 · NCT05724121LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 to 81 · All sexes · Updated Aug 6, 2026 · NCT05990465Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06675123A Long-term Extension Study of PCI-32765 (Ibrutinib)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT01804686A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07285044This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07121946From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.